You’ve probably heard of THC and CBD, but another one of the many cannabinoids in the cannabis plant is Cannabigerol, or CBG. CBG is the precursor from which all other cannabinoids are synthesized, which is why it’s often referred to as the “mother” or “stem cell” of cannabinoids. This unique property imbues CBG with enormous therapeutic promise, making it a subject of great interest for researchers and consumers alike. Unlike CBD, which has a relatively low affinity for cannabinoid receptors and acts mostly through indirect interactions with the endocannabinoid system, CBG is thought to elicit its therapeutic effects directly through interaction with the CB1 and CB2 cannabinoid receptors in the brain. However, CBG is a non-psychoactive cannabinoid much like CBD. This allows us to harness the beneficial effects of this compound without any intoxicating effects.
Research is relatively sparse regarding the therapeutic benefits of CBG, when compared to the apparent wealth of information available on THC and CBD within the cannabis science community. But there are early studies linking the compound to a whole host of potential therapeutic uses, such as:
CBG has been shown to have antibacterial properties, particularly for MRSA. Methicillin-resistant Staphylococcus aureus or "MRSA" is a type of staph infection that is resistant to methicillin (a common type of antibiotic), rendering it a particularly threatening or even fatal bacterial infection. In a 2008 study, CBG showed potential for treating MRSA as an antibacterial agent. Dr. Solomon said this is an area where CBG shows real promise. "It's thought to help with MRSA," he said. "CBG has potential to treat bacteria that are resistant to traditional antibiotics."
We expect in 2021 more and more hemp farmers will plant CBG-rich clones as phenotypes are isolated for CBG production. We hope you enjoyed learning about one of the newest cannabinoids to be extracted and researched and how CBG may be right for you.